Managing Risks with Biologics

被引：29
作者：
Click B. [1 ]
Regueiro M. [1 ]
机构：
[1] Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH
来源：
Current Gastroenterology Reports | 2019年 / 21卷 / 1期
关键词：
Biologics; Crohn’s disease; Infection; Safety; Ulcerative colitis;
D O I：
10.1007/s11894-019-0669-6
中图分类号：
学科分类号：
摘要：
Purpose of Review: With a rapidly evolving complement of advanced targeted therapies in inflammatory bowel disease, additional safety and side effect concerns emerge. It is the purpose of this review to consider various risks with biologic therapies in inflammatory bowel disease and discuss mitigating strategies. Recent Findings: Two recently approved monoclonal antibodies (vedolizumab and ustekinumab) and a Janus kinase inhibitor small molecule (tofacitnib) have introduced a number of novel safety and risk considerations. We review the clinical trial and real-world safety data to date on these agents as well as review new data and considerations with anti-tumor necrosis factor agents. New vaccines for varicella zoster virus, hepatitis B virus, and high-dose influenza have been studied, and we discuss the clinical importance of these findings. Lastly, we make management recommendations in the event of particular side effects or complications. Summary: Understanding the risks of new agents in inflammatory bowel disease, potential mitigating strategies, and management considerations is important to achieving and maintaining clinical outcomes in IBD patients. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 73 条
  • [61] Seror R., Richez C., Sordet C., Rist S., Gossec L., Direz G., Et al., Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey, Rheumatology (Oxford, England), 52, 5, pp. 868-874, (2013)
  • [62] Lozeron P., Denier C., Lacroix C., Adams D., Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy, Arch Neurol, 66, 4, pp. 490-497, (2009)
  • [63] Badat Y., Meissner W.G., Laharie D., Demyelination in a patient receiving ustekinumab for refractory Crohn's disease, J Crohns Colitis, 8, 9, pp. 1138-1139, (2014)
  • [64] Tillack C., Ehmann L.M., Friedrich M., Laubender R.P., Papay P., Vogelsang H., Stallhofer J., Beigel F., Bedynek A., Wetzke M., Maier H., Koburger M., Wagner J., Glas J., Diegelmann J., Koglin S., Dombrowski Y., Schauber J., Wollenberg A., Brand S., Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment, Gut
  • [65] Ghabril M., Bonkovsky H.L., Kum C., Davern T., Hayashi P.H., Kleiner D.E., Et al., Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases, Clin Gastroenterol Hepatol, 11, 5, pp. 558-564, (2013)
  • [66] Rodrigues S., Lopes S., Magro F., Cardoso H., Horta e Vale A.M., Marques M., Et al., Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases, World J Gastroenterol, 21, 24, pp. 7584-7588, (2015)
  • [67] Shelton E., Chaudrey K., Sauk J., Khalili H., Masia R., Nguyen D.D., Yajnik V., Ananthakrishnan A.N., New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease, Aliment Pharmacol Ther, 41, 10, pp. 972-979, (2015)
  • [68] Bessissow T., Renard M., Hoffman I., Vermeire S., Rutgeerts P., Van Assche G., Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy, Aliment Pharmacol Ther, 36, 4, pp. 312-323, (2012)
  • [69] Hastings R., Ding T., Butt S., Gadsby K., Zhang W., Moots R.J., Deighton C., Neutropenia in patients receiving anti-tumor necrosis factor therapy, Arthritis Care Res, 62, 6, pp. 764-769, (2010)
  • [70] Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.F., Sandborn W.J., van Assche G., Axler J., Kim H.J., Danese S., Fox I., Milch C., Sankoh S., Wyant T., Xu J., Parikh A., Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 8, pp. 699-710, (2013)
12345678